Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

History

 
Health care that is driven by quality across a range of services within the hospital system is attractive and marketable to other countries. The image of hospitals as upmarket hotels can be transported but only through the application of consistent, safe and considerate patient care. Establishment of a hospital accreditation system in Lebanon, once fully implemented will pave the way for the provision of good quality of health care. As the accreditation system matures the standards will further develop and quality assurance and quality improvement will lead on to the more precise measurement of health outcomes.

A broad range of quality measures will be discussed in this paper to show that when the ethic of quality is embedded within the health system, the delivery, utilisation and growth of acute hospital services in Lebanon is more attractive to local patients and neighboring countries. It is vital that the concepts of quality assurance and quality improvement be seen as critical and not as an adjunct to hotel services, and quality and accommodation standards are not viewed in isolation. The development of quality hotel services is linked quite clearly to quality generally, whether it is in the building/infrastructural component, the furbishing component, equipment or the patient care services.

Quality assurance principles and hospital accreditation address quality of care deficiencies and harmful and/or wasteful practices, and can stimulate debate between public and private providers, policy makers and consumers on what practices conform to the latest reliable evidence. This promotes a wider dissemination of knowledge. Increased knowledge and awareness by the public ensures that hospitals achieve greater throughputs because of the public's faith that the hospital is able to meet the wide range of quality standards.

Hospital management have often remarked during visits of the OPCV Survey Team that unless a hospital provided "the full options"- that is a complete range of the latest sophisticated medical technology - then it was not considered to be a good hospital. Scant attention is paid to whether the size and complexity of the hospital warrants a complete range of equipment, or indeed whether the hospital can provide the qualified staff necessary to operate such equipment safely. The image of what constitutes a good hospital is generally supported by the current Hospital Classification system and it this image that is required to be changed through the implementation of quality assurance/improvement to support the marketing of Lebanon's hospital services to other countries. A public education campaign is therefore a concomitant exercise to be carried out in parallel with the development of the quality approach .
    5
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AD01 SANDIMMUN NEORAL SOFT GELATIN B Ciclosporin - 50mg 50mg Capsule, soft gelatin 4,309,703 L.L
L04AD01 SANDIMMUN NEORAL SOFT GELATIN B Ciclosporin - 25mg 25mg Capsule, soft gelatin 2,385,320 L.L
L04AD01 SANDIMMUN NEORAL SOFT GELATIN B Ciclosporin - 100mg 100mg Capsule, soft gelatin 8,264,592 L.L
L04AD01 SANDIMMUN NEORAL B Ciclosporin - 100mg/ml 100mg/ml Solution 8,264,592 L.L
L04AC18 SKYRIZI BioTech Risankizumab - 75mg 75mg Injectable solution 194,911,251 L.L
L04AC18 SKYRIZI BioTech Risankizumab - 150mg 150mg Injectable solution 194,911,251 L.L
L04AC05 STELARA BioTech Ustekinumab - 90mg 90mg Injectable solution L.L
L04AC05 STELARA BioTech Ustekinumab - 45mg 45mg Injectable solution 151,777,679 L.L
L04AC05 STELARA BioTech Ustekinumab - 45mg 45mg Injectable solution 151,777,679 L.L
L04AC05 STELARA BioTech Ustekinumab - 90mg 90mg Injectable solution 151,777,679 L.L
L04AC05 STELARA BioTech Ustekinumab - 90mg 90mg Injectable solution 151,777,679 L.L
L04AC05 STELARA BioTech Ustekinumab - 130mg 130mg Injectable concentrate for solution 226,619,295 L.L
L04AC02 SIMULECT BioTech Basiliximab - 20mg 20mg Injectable powder + solvent 131,822,828 L.L
L04AB06 SIMPONI BioTech Golimumab - 50mg/0.5ml 50mg/0.5ml Injectable solution 72,719,241 L.L
L04AB06 SIMPONI BioTech Golimumab - 100mg/1ml 100mg/1ml Injectable solution 72,719,241 L.L
L04AA27 SCLEMOD G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule L.L
L04AA27 SCLEMOD G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule 18,264,981 L.L
L04AA27 SCLEMOD G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule 17,079,643 L.L
L04AA27 SCLEMOD G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule L.L
L04AA10 SIROMUNE G Sirolimus - 1mg 1mg Tablet, film coated 18,729,193 L.L
L03AX03 SII-ONCO-BCG G Bacillus Calmette- Guerin Strain - 40mg/ml (1-8x10?CFU) 40mg/ml Injectable dry powder 6,987,981 L.L
L01XX02 SPECTRILA BioTech Asparaginase, recombinant - 10,000IU 10,000IU Injectable powder for concentrate for solution 21,370,813 L.L
L01FG01 STIVANT BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 27,359,527 L.L
L01FG01 STIVANT BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrate for solution 14,719,570 L.L
L01EX05 STIVARGA B Regorafenib - 40mg 40mg Tablet, film coated L.L
L01EX05 STIVARGA B Regorafenib - 40mg 40mg Tablet, film coated 262,387,816 L.L
L01EX01 SUTENT B Sunitinib maleate - 12.5mg 12.5mg Capsule L.L
L01EX01 SUTENT B Sunitinib maleate - 50mg 50mg Capsule L.L
L01EX01 SUTENT B Sunitinib maleate - 12.5mg 12.5mg Capsule 54,006,801 L.L
L01EX01 SOVIDEX G Sunitinib maleate - 12.5mg 12.5mg Capsule 36,042,560 L.L
    5
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025